Omnicell, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; unaudited. Omnicell sells medication and medical-supply dispensing systems and related services, primarily to hospitals and healthcare facilities. The company reports one operating segment.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Product revenue | $48.5 million | $42.6 million |
| Services and other revenue | $15.6 million | $14.6 million |
| Total revenue | $64.1 million | $57.2 million |
| Gross profit / margin | $35.7 million / 55.8% | $31.7 million / 55.4% |
| Operating income / margin | $3.6 million / 5.8% | $1.0 million / 1.8% |
| Net income | $2.4 million | $0.7 million |
| Diluted earnings per share | $0.07 | $0.02 |
| Cash provided by operating activities | $7.3 million | $3.1 million |
Product gross margin was 58.2% versus 58.1%; service gross margin was 48.2% versus 47.4%. Cash and cash equivalents were $201.4 million at March 31, with $8.1 million of short-term investments, for total cash and investments of $209.5 million. Total current assets were $291.8 million and current liabilities $62.3 million. The balance sheet reports no borrowings or other interest-bearing debt. Management said existing cash and operating cash flows should cover working capital and capital expenditures for at least the next 12 months, before considering the pending acquisition.
Changes versus the prior comparable period
- Revenue rose 12.2% year over year, with product revenue up 14.0% and services and other revenue up 7.1%.
- Gross margin improved 0.4 percentage points. Net income increased to $2.4 million from $0.7 million.
- Research and development expense rose 34.2% to $6.5 million, partly because no software development costs qualified for capitalization in Q1 2012; Q1 2011 included $1.8 million of capitalized software development.
- Selling, general and administrative expense edged down 0.6%. The prior-year period included a $1.0 million Medacist litigation settlement accrual and $0.5 million in related legal fees.
- Operating cash flow increased to $7.3 million, helped by higher net income and an inventory reduction, compared with inventory growth in the prior-year period. Investing cash use declined to $1.5 million; financing provided $3.8 million, versus $0.8 million used in Q1 2011, which included $4.7 million of share repurchases.
- Compared with Q4 2011, Q1 2012 revenue rose 1.9%, but gross margin declined to 55.7% from 57.0%, primarily as service margin fell to 48.2% from 52.2%.
Outlook, risks and notable items
- Management forecast 2012 revenue growth of approximately 7%–8% year over year, citing existing orders and expected lease renewals. It expected service revenue and gross profit to continue increasing at a similar rate as the installed base expands.
- On April 26, 2012, Omnicell agreed to acquire MedPak Holdings, parent of MTS Medication Technologies, for $156.0 million in cash, subject to adjustments. Closing remained subject to customary conditions, including expiration of the Hart-Scott-Rodino waiting period. The quarter’s financial results exclude MTS.
- The acquisition would use a substantial portion of available cash. Management did not provide an estimate of the acquisition’s financial effect beyond the purchase price. The filing identifies integration, employee and customer retention, execution, and transaction-completion risks.
- Operating results depend on customer capital budgets and installation schedules; revenue is generally recognized after installation, which can occur weeks to months after an order. Competition, healthcare-sector spending constraints, product execution, supplier concentration, and regulatory or technology changes are additional risks.
- New facilities create commitments: the planned Mountain View headquarters lease has a stated base commitment of approximately $40.0 million over 120 months, and the Milpitas facility lease approximately $1.8 million over 60 months. Management also warned of added costs or disruption if construction or facility moves are delayed.
- Management reported no legal proceedings it believed would materially affect financial position or results, no material changes in market-risk disclosures, and effective disclosure controls as of March 31, 2012.
Most important facts for investors to verify
- Whether the MTS acquisition closed, its final cash cost and funding, and the acquired business’s subsequent contribution to revenue, earnings, and cash flow.
- Whether Omnicell achieved the 7%–8% 2012 revenue-growth outlook and delivered expected lease renewals and installations on schedule.
- Whether service margins recover from the sequential Q1 decline and whether revenue growth translates into sustained operating-margin improvement.
- Cash, liquidity, and any financing needs after the acquisition and planned facility commitments.
- Customer spending and installation timing, competitive pressures, and the potential effects of supplier dependence and facility-transition delays.